Table 1.

Summary of SGLT2 inhibitor cardio-renal benefits

SGLT2 inhibitor	CVOTs	Licensed indications	Use in older adult	Cardio-renal benefits
Dapagliflozin	DECLARE TIMI-58 [44] DAPA-HF [45] DAPA-CKD [36]	T2DM HF CKD	≥65 years	Reduction in CV mortality Reduction in HHF Improvement in HF-related health status Reduction in renal adverse events
Canagliflozin	CANVAS [46] CREDENCE [47]	T2DM	≥65 years Caution: Renal function and risk of volume depletion should be taken into account	Prevention of MACE Reduction in HHF Reduction in systolic and diastolic blood pressure Reduction in renal adverse events
Empagliflozin	EMPA-REG OUTCOMES [48] EMPEROR- REDUCED [49] EMPEROR-PRESERVED [50]	T2DM HF	≥75 years Caution: risk of volume depletion should be taken into account ≥ 85 years: not recommended	Reduction in CV mortality Reduction in HHF Reduction in renal adverse events
Ertugliflozin	VERTIS-CV [51]	T2DM	≥65 years Caution: Renal function and risk of volume depletion should be taken into account	Reduction in HHF